Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Improving MDS management: new targets, drug combinations, and personalized and cellular therapies

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, and Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, discuss the limitations of current standards of care for myelodysplastic syndromes (MDS) and explore emerging treatment targets and strategies for this condition. Dr Sallman and Dr Brunner first highlight the importance of using the findings from large Phase III clinical studies to help us determine the role of new agents in treatment regimens and to test different drug combinations to eventually develop a new improved approach to MDS treatment. They then discuss how advances in technologies such as sequencing as well as the development of improved molecular classification and risk stratification models will enable us to personalize treatment for MDS patients. Moving forward, Dr Sallman and Dr Brunner comment on the potential of targeting splicing mutations in MDS, outlining recent studies evaluating such strategies. Finally, Dr Sallman and Dr Brunner share their thoughts on the current role of cellular therapies in MDS, highlighting their potential in TP53-mutated MDS. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.